--- title: "Nuo Therapeutics (AURX) stock: news and investor profile" url: "https://aibio.space/companies/nuo-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Nuo Therapeutics, Inc. (OTC: AURX), United States. Listing facts, related biotech companies and news on aibio.space." --- AURX Nuo Therapeutics, Inc. OTC · United States # Nuo Therapeutics (AURX) news Debt Financing · 2026-10-06 ## [Nuo Therapeutics receives $325,000 second funding under loan](https://aibio.space/news/nuo-therapeutics-receives-325-000-second-funding-under-loan/) Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028. ## Latest Nuo Therapeutics news 1. 2026-05-29 Debt Financing [Nuo Therapeutics closes $675,000 interim loan at 12% interest](https://aibio.space/news/nuo-therapeutics-closes-675-000-interim-loan-12-percent-interest/) Five lenders, including a director and a holder of more than 5% of the stock, joined the interim tranche. The notes pay 12% interest in warrants rather than cash and mature December 31, 2028. ## Nuo Therapeutics at a glance - **Ticker**: AURX - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $449,325 ### Related companies - [PyroGenesis Canada](https://aibio.space/companies/pyrogenesis-canada/) OTC: PYRGF - [Intercure](https://aibio.space/companies/intercure/) NASDAQ: INCR - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) NASDAQ: CARL - [OmniAb](https://aibio.space/companies/omniab/) NASDAQ: OABI - [NeuroPace](https://aibio.space/companies/neuropace/) NASDAQ: NPCE - [Vivos Therapeutics](https://aibio.space/companies/vivos-therapeutics/) NASDAQ: VVOS - [IM Cannabis](https://aibio.space/companies/im-cannabis/) NASDAQ: IMCC - [Burning Rock Biotech](https://aibio.space/companies/burning-rock-biotech/) NASDAQ: BNR ### Also on OTC - [ENvue Medical](https://aibio.space/companies/envue-medical/) FEED - [Vireo Growth](https://aibio.space/companies/vireo-growth/) VREOF - [Accustem Sciences](https://aibio.space/companies/accustem-sciences/) ACUT - [ENDONOVO THERAPEUTICS, INC.](https://aibio.space/companies/endonovo-therapeutics/) ENDV - [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) RBII - [Inhibitor Therapeutics](https://aibio.space/companies/inhibitor-therapeutics/) INTI ## Nuo Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$2.5 million](https://www.sec.gov/Archives/edgar/data/1091596/000143774926010360/) | [-$2.3 million](https://www.sec.gov/Archives/edgar/data/1091596/000143774926010360/) | | Cash from operations | [-$864,971](https://www.sec.gov/Archives/edgar/data/1091596/000143774926010360/) | [-$2.2 million](https://www.sec.gov/Archives/edgar/data/1091596/000143774926010360/) | | Cash and equivalents | [$548,946](https://www.sec.gov/Archives/edgar/data/1091596/000143774926028053/) | [$283,714](https://www.sec.gov/Archives/edgar/data/1091596/000143774926010360/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $449,325. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nuo Therapeutics What is the ticker symbol of Nuo Therapeutics? Nuo Therapeutics, Inc. trades under the ticker AURX on OTC. Where is Nuo Therapeutics listed? Nuo Therapeutics, Inc. is listed on OTC. Which country or territory is Nuo Therapeutics listed under? Our directory records Nuo Therapeutics, Inc. under United States. Does aibio.space cover Nuo Therapeutics? aibio.space lists Nuo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Nuo Therapeutics profitable? Nuo Therapeutics, Inc. reported a net loss of $2.5 million for the fiscal year ended Dec 31, 2025, and used $864,971 of cash in operations, per its annual report to the SEC. How much cash does Nuo Therapeutics have? $449,325 in cash at Jun 30, 2026, per its 10-Q. What is the latest Nuo Therapeutics (AURX) stock news? Our latest story on Nuo Therapeutics, dated Oct 6, 2026: "Nuo Therapeutics receives $325,000 second funding under loan". Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028. [Source](https://aibio.space/news/nuo-therapeutics-receives-325-000-second-funding-under-loan/). Does Nuo Therapeutics have debt, a term loan or convertible notes? Our latest debt story, dated Oct 6, 2026: "Nuo Therapeutics receives $325,000 second funding under loan". Director Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028. [Source](https://aibio.space/news/nuo-therapeutics-receives-325-000-second-funding-under-loan/). How can I follow Nuo Therapeutics (AURX) news? Press Follow on this page to add Nuo Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Nuo Therapeutics so far, in Debt Financing. ## Investor discussion: Nuo Therapeutics Members talk about Nuo Therapeutics (AURX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:AURX on TradingView](https://www.tradingview.com/symbols/OTC-AURX/). ## Listing details Nuo Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker AURX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nuo Therapeutics, Inc. - **Ticker**: AURX - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nuo-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nuo Therapeutics (AURX) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/nuo-therapeutics/